Ignite Creation Date:
2025-12-25 @ 12:14 AM
Ignite Modification Date:
2025-12-25 @ 10:16 PM
Study NCT ID:
NCT05183958
Status:
UNKNOWN
Last Update Posted:
2022-01-11
First Post:
2021-12-21
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer
Sponsor:
Zhejiang Cancer Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-12-31
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-12-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2021-12-21
First Submit QC Date:
None
Study First Post Date:
2022-01-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-12-21
Last Update Post Date:
2022-01-11
Last Update Post Date Type:
ACTUAL